TG Therapeutics Inc. (TGTX)
Company Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.
The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys.
The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A.
TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Country | United States |
IPO Date | May 3, 2010 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 338 |
CEO | Michael S. Weiss Esq. |
Contact Details
Address: 2 Gansevoort Street New York, New York United States | |
Website | https://www.tgtherapeutics.com |
Stock Details
Ticker Symbol | TGTX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001001316 |
CUSIP Number | 88322Q108 |
ISIN Number | US88322Q1085 |
Employer ID | 36-3898269 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Michael S. Weiss Esq. | Chairman, Chief Executive Officer & President |
Sean A. Power CPA | Chief Financial Officer, Corporate Secretary & Treasurer |
Adam Waldman | Chief Commercialization Officer |
Jenna Bosco | Senior Vice President of Corporate Communications |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 18, 2025 | 4 | Filing |
Mar 11, 2025 | 4 | Filing |
Mar 03, 2025 | 10-K | Annual Report |
Mar 03, 2025 | 8-K | Current Report |
Jan 30, 2025 | 4 | Filing |
Jan 30, 2025 | 4 | Filing |
Jan 14, 2025 | 8-K | Current Report |
Jan 08, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 07, 2025 | 4 | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |